Ad-hoc disclosure under Art.17 MAR

[et_pb_section fb_built=“1″ _builder_version=“3.22″][et_pb_row _builder_version=“3.25″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“][et_pb_column type=“4_4″ _builder_version=“3.25″ custom_padding=“|||“ custom_padding__hover=“|||“][et_pb_text _builder_version=“4.4.7″ hover_enabled=“0″]

HAEMATO AG: Ad-hoc disclosure under Article 17 MAR

HAEMATO AG: MPH Health Care AG brings its shares in HAEMATO AG to M1 Kliniken AG as part of a non-cash capital increase.
Today MPH Health Care AG and M1 Kliniken AG informed us that MPH Health Care AG transfers all of its registered shares in HAEMATO AG to M1 Kliniken AG with effect from 1.07.2020. MPH Health Care AG brings the shares in to M1 Kliniken AG within the scope of a non-cash capital increase.

About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE000619070
WKN: 619070
Stock exchange code: HAE

 

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]